U.S. Markets closed

AstraZeneca PLC (AZN.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
5,130.00+11.00 (+0.21%)
At close: 5:06PM BST
Interactive chart
Previous Close5,119.00
Open5,125.00
Bid4,865.00 x 6100
Ask5,200.00 x 13000
Day's Range5,102.00 - 5,188.66
52 Week Range3,680.00 - 5,505.00
Volume2,188,205
Avg. Volume2,350,629
Market Cap64.93B
Beta0.61
PE Ratio (TTM)19.21
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (4.20%)
Ex-Dividend Date2017-02-16
1y Target EstN/A
  • Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
    Zacks6 hours ago

    Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab

    Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

  • Reuters8 hours ago

    Severe asthma drug shows AstraZeneca promise beyond cancer

    AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year. Benralizumab will compete with GlaxoSmithKline's Nucala and Teva's Cinqair - two other new antibody drugs for severe asthma - but AstraZeneca believes its product's potency and convenient dosing could give it an edge. While most investor focus is on AstraZeneca's cancer research, particularly the immunotherapy drug durvalumab , the company also has a long history in respiratory therapy that it plans to build on with benralizumab.

  • Financial Times11 hours ago

    [$$] AstraZeneca sells Seloken European rights for $300m

    AstraZeneca, the Anglo-Swedish pharmaceuticals group, has sold the European commercial rights to its Seloken heart medicines in a deal worth more than $300m, as it moves to focus on new products in what ...